[Federal Register Volume 86, Number 36 (Thursday, February 25, 2021)]
[Notices]
[Pages 11548-11549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03873]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Engineered 
Tumor Infiltrating Lymphocytes for Cancer Therapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this Notice to Iovance 
Biotherapeutics, Inc. (``Iovance''), headquartered in San Carlos, CA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before March 12, 2021 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer 
Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484; 
Email: <a href="/cdn-cgi/l/email-protection#a2c3ccc6db8cc0d7d0c9c7e2cccbca8cc5cdd4"><span class="__cf_email__" data-cfemail="82e3ece6fbace0f7f0e9e7c2ecebeaace5edf4">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

Intellectual Property

E-068-2018: Tethered Interleukin-15 and Interleukin-21

    1. US Provisional Patent Application 62/628,454, filed February 9, 
2018 (E-068-2018-0-US-01);
    2. International Patent Application PCT/US2019/016975, filed 
February 7, 2019 (E-068-2018-0-PCT-02);
    3. Australian Patent Application 2019218785, filed August 7, 2020 
(E-068-2018-0-AU-03);
    4. Chinese Patent Application 201980012443.3, filed August 7, 2020 
(E-068-2018-0-CN-04);
    5. European Patent Application 19709154.9, filed August 18, 2020 
(E-068-2018-0-EP-05);
    6. United States Patent Application 16/964,796, filed July 24, 2020 
(E-068-2018-0-US-06); and
    7. Canadian Patent Application 3,090,512, filed August 5, 2020 (E-
068-2018-0-CA-07).
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the following:
    ``The use of the Licensed Patent Rights to develop, manufacture, 
distribute, sell, and use unselected whole autologous tumor 
infiltrating lymphocyte (TIL) adoptive cell therapy products for the 
treatment of metastatic melanoma, lung, breast, bladder, and HPV-
positive cancers. Specifically excluded from this Agreement are methods 
of generating or using selected subpopulations of TIL and the use of T 
cell receptors isolated from TIL.''
    E-068-2018 is primarily directed to recombinant constructs for the 
co-expression of Interleukins-15 and 21 (IL-15 and 21). IL-15 and IL-21 
have been reported to support the function of anti-tumor T cells; 
however, their

[[Page 11549]]

clinical utility has been constrained, in part, by dose-limiting 
toxicity following systemic administration and the need for repeated 
dosing. The subject invention addresses these limitations through 
synthetic IL-15/21 sequences which incorporate flexible linker regions 
and cell membrane anchors. T cells engineered to express these 
constructs experience autocrine IL-15/21 signaling leading to enhanced 
anti-tumor function in vivo.
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published Notice, the National 
Cancer Institute receives written evidence and argument establishing 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially and may be made 
publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: February 12, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2021-03873 Filed 2-24-21; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>